Publication | Open Access

Autophagy inhibitors increase the susceptibility of KRAS-mutant human colorectal cancer cells to a combined treatment of 2-deoxy-D-glucose and lovastatin

Tumor BiologyMitophagyCell AutophagyOncologyAutophagy InhibitorsMedicineAutophagyCell DeathAnti-cancer AgentPharmacologyCell BiologyTumor MicroenvironmentCancer ResearchCombined Treatment